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Pro-Osteogenic Phenotype of Human
Aortic Valve Interstitial Cells Is Associated With
Higher Levels of Toll-Like Receptors 2 and 4 and
Enhanced Expression of Bone Morphogenetic Protein 2
Xiaoping Yang, PHD, David A. Fullerton, MD, Xin Su, MD, Lihua Ao, BS,
Joseph C. Cleveland, JR, MD, Xianzhong Meng, MD, PHD
Denver, Colorado
Objectives Our aim was to determine whether aortic valve interstitial cells (AVICs) and pulmonary valve interstitial cells
(PVICs) differ in expression of toll-like receptor (TLR)2 and TLR4, response to TLR agonists, and osteogenic phe-
notypic changes.
Background Calcific stenosis occurs frequently in aortic valves but rarely in pulmonary valves. Studies have implicated AVICs
in the inflammation associated with calcification and progression to stenosis. We previously reported that hu-
man AVICs express functional TLR2 and TLR4 and that stimulation of these receptors induces pro-osteogenic
factor expression.
Methods Human aortic and pulmonary valve leaflets from the same heart were collected and interstitial cells isolated.
Results Aortic valves express more TLR2 and TLR4, in both tissue and isolated interstitial cells, than pulmonary valves.
After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-
osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater os-
teogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs. Silenc-
ing TLR2 and TLR4 in AVICs reduced BMP-2 expression and ALP activity to PVIC levels. ALP activity in AVICs
induced by TLR2 and TLR4 agonists was abolished by BMP antagonism with Noggin and mimicked by stimula-
tion with recombinant BMP-2. AVICs isolated from stenotic valves had greater expression of TLR2 and TLR4 and
a greater BMP-2 response than AVICs from normal valves.
Conclusions Greater expression of TLR2 and TLR4 and greater pro-inflammatory and pro-osteogenic responses to TLR2 and
TLR4 agonists in AVICs than PVICs are associated with osteogenic phenotypic changes. These innate immune
receptors may play a critical role in aortic valve calcification and stenosis. (J Am Coll Cardiol 2009;53:
491–500) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.052i
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aortic valve calcification, which affects 27% of the U.S.
opulation older than age 60 years, often progresses to
alcific aortic stenosis (1). Despite its poor prognosis, the
nly therapy currently available for severe, symptomatic
ortic stenosis is valve replacement. Several mechanisms for
eart valve calcification have been proposed, including
atrix remodeling, lipid accumulation in the valve, and
ysfunction of the renin-angiotensin system (2). Clinical
rials of 3-hydroxy-3-methylglutaryl coenzyme A reductase
rom the Division of Cardiothoracic Surgery, Department of Surgery, University of
olorado Denver, Denver, Colorado. Supported by American Heart Association
rant 0850148Z and the Academic Enrichment Fund of University of Colorado
enver.n
Manuscript received July 22, 2008; revised manuscript received September 22,
008, accepted September 29, 2008.nhibitors (statins) are underway, but none has yet shown a
ignificant benefit (3).
Several studies have demonstrated an association between
nflammation and aortic valve calcification (4). Macro-
hages, T-lymphocytes, and pro-inflammatory mediators
uch as interleukin-1, transforming growth factor-beta, and
umor necrosis factor-alpha have all been found in calcified
uman heart valves (2). But it is not yet clear that inflam-
ation causes valve calcification or what molecular mecha-
isms may be involved. We recently found that human
ortic valve interstitial cells (AVICs) express functional
oll-like receptor (TLR)2 and TLR4 (5), important medi-
tors of the innate immune response and inflammation.
Valve interstitial cells (VICs), the major cellular compo-
ents of heart valve leaflets, have the dual ability to secrete
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tain valvular contractile function
(6). AVICs stimulated with TLR
agonists up-regulate bone mor-
phogenetic protein (BMP)-2 and
runt-related transcription factor
2 (Runx2) (5), which have both
been found in calcified valve leaf-
lets (7,8). In addition, AVICs
stimulated with BMP-2 up-
regulate alkaline phosphatase
(ALP) (9), and formation of cal-
cified nodules in VICs is depen-
dent on ALP activity (10). But
the mechanisms by which AVICs
up-regulate these pro-osteogenic
actors are unclear. Because calcification occurs frequently in
ortic valves but rarely in pulmonary valves, comparing
ro-osteogenic signaling in AVICs and pulmonary valve
nterstitial cells (PVICs) may provide mechanistic insights.
We hypothesize that differential TLR expression and
ifferential response to TLR agonists distinguish AVICs from
VICs and are associated with a pro-osteogenic phenotype. In
his study we will examine whether: 1) human aortic and
ulmonary valves, both tissue and isolated interstitial cells,
xpress different levels of TLR2 and TLR4; 2) stimulation
f TLR2 and TLR4 results in differential expression of
ro-inflammatory and pro-osteogenic factors in AVICs and
VICs; 3) reducing cellular TLR2 and TLR4 levels via
ilencing influences the pro-osteogenic response in AVICs;
) BMP-2 links TLR2 and TLR4 to osteogenic phenotypic
hanges; and 5) TLR2, TLR4, and BMP-2 expression differ
n AVICs isolated from normal versus stenotic valves.
ethods
ell isolation and culture. Normal aortic and pulmonary
alves were collected from 4 explanted hearts of heart
ransplant recipients and 2 unusable donor hearts (from 4
ales and 2 males, mean age 58.3  6.6 years). Explanted
earts were from patients of the University of Colorado
ospital or the Denver Veterans Administration Medical
enter with cardiomyopathy but no history of heart valve
isease. Stenotic aortic valves were collected from 3 patients
ho underwent valve replacement surgery for calcific aortic
tenosis (1 male/2 female patients, mean age 54.7  16.2
ears). All patients gave written informed consent, and this
tudy was approved by the Colorado Multiple Institutional
eview Board.
After harvest, aortic and pulmonary valve leaflets were
rocessed as previously described (5). All stenotic valves had
vert calcium deposits, and interstitial cells were isolated
rom soft tissue adjacent to calcium deposits.
AVICs and PVICs were isolated and cultured as previ-
usly described (5). Cells from passages 3 to 7 at approxi-
Abbreviations
and Acronyms
ALP  alkaline
phosphatase
AVIC  aortic valve
interstitial cell
BMP  bone
morphogenetic protein
PVIC  pulmonary valve
interstitial cell
Runx2  runt-related
transcription factor 2
TLR  toll-like receptor
VIC  valve interstitial cellately 90% confluence were used for all experiments. For sertain experiments, cells were cultured in conditioning
edium (growth medium with 10 mmol/l beta-
lycerophosphate, 10 nmol/l vitamin D3, and 10 nmol/l
examethasone), a modification of the osteogenic medium
sed by Osman et al. (9). The medium was changed every 3
ays. All comparative experiments on AVICs and PVICs
sed cells isolated from the same heart. Cells were treated
ith peptidoglycan (Staphylococcus aureus, 10 g/ml), lipo-
olysaccharide (Escherichia coli 0111:B4, 200 ng/ml), re-
ombinant human BMP-2 (100 ng/ml, R&D Systems,
inneapolis, Minnesota), and/or Noggin (470 ng/ml,
&D Systems) for the time course indicated. Unless oth-
rwise stated, reagents were purchased from Sigma (St.
ouis, Missouri).
mmunoblotting. Protein samples were separated on 4%
o 20% minigels and transferred onto nitrocellulose mem-
ranes (Bio-Rad Laboratories, Hercules, California). Pro-
eins were detected using primary antibodies to TLR2 and
LR4 (Imgenex, San Diego, California), BMP-2 (ProSci,
oway, California), BMP-4 (Assay Designs, Ann Arbor,
ichigan), or Runx2 (Novus Biologicals, Littleton, Colorado)
nd corresponding peroxidase-linked secondary antibodies
Cell Signaling Technology, Danvers, Massachusetts). Blots
ere developed with enhanced chemiluminescence reagent and
computerized densitometer (Molecular Dynamics, Sunny-
ale, California) was used to measure band density.
low cytometry. Cell-surface expression of TLR2 and
LR4 was detected using phycoerythrin-conjugated TLR2
nd TLR4 antibodies (Imgenex) as previously described (11).
ucleotide Sequences ofLR2, TLR4, and S rambled siRNA
Table 1 Nucleotide Sequences ofTLR2, TLR4, and Scrambled siRNA
siRNA Pool
TLR2
Sense 5=-AAAUCGAGAGCUGCGAUAUU-3=
Antisense 5=-PUAUCGCAGCUCUCAGAUUUUU-3=
Sense 5=-AGGUAAAGUGGAAACGUUAUU-3=
Antisense 5=-PUAACGUUUCCACUUUACCUUU-3=
Sense 5=-UGUUUGGAACUGCGAGAUAUU-3=
Antisense 5=-PUAUCUCGCAGUUCCAAACAUU-3=
Sense 5=-AGUAGGAAUGCAAUAACUAUU-3=
Antisense 5=-PUAGUUAUUGCAUUCCUACUUU-3=
TLR4
Sense 5=-UGGUGGAAGUUGAACGAAUUU-3=
Antisense 5=-PAUUCGUUCAACUUCCACCAUU-3=
Sense 5=-GUUUAGAAGUCCAUCGUUUUU-3=
Antisense 5=-PAAACGAUGGACUUCUAAACUU-3=
Sense 5=-CAUUGAAGAAUUCCGAUUAUU-3=
Antisense 5=-PUAAUCGGAAUUCUUCAAUGUU-3=
Sense 5=-GGAAAAUGGUGUAGCCGUUUU-3=
Antisense 5=-PAACGGCUACACCAUUUUCCUU-3=
Scrambled siRNA
Sense 5=-UAGCGACUAAACACAUCAAUU-3=
Antisense 5=-PUUGAUGUGUUUAGUCGCUAUU-3=iRNA  small interfering ribonucleic acid; TLR  toll-like receptor.
C
d
R
S
u
n
a
a
A
l
N
l
g
p
s
a
s
R
(
a
E
A
a
w
(
s
C
A
P
493JACC Vol. 53, No. 6, 2009 Yang et al.
February 10, 2009:491–500 Comparison of Aortic and Pulmonary Valveshemokine assay. Chemokine levels in cell culture me-
ium were determined using a BioPlex immunoassay (Bio-
ad Laboratories).
ilencing TLR2 and TLR4. Silencing TLR2 and TLR4,
sing TLR2 or TLR4 small interfering ribonucleic acid (60
mol/l, Dharmacon, Lafayette, Colorado), was performed
s previously described (11). Table 1 lists sequences of sense
nd antisense siRNA nucleotides.
LP activity assay and staining. For the assay, cells were
ysed with lysis buffer (20 mmol/l Tris-HCl, 150 mmol
aCl, 0.2% NP40, and 10% glycerol), pH 8.0, and cell
ysates (5 g protein) were incubated in a buffer (0.1 mol/l
lycylglycine, 10 mmol/l MgCl2, 10 mmol/l p-nitrophenyl
Figure 1 AVs Express More TLR2 and TLR4 Than PVs
(A) Representative immunoblots of aortic and pulmonary valve tissue homogenate
receptor (TLR)2 and TLR4 than pulmonary valves (PVs) from the same heart. (B) R
interstitial cell (PVIC) lysates with desitometric data (n  6) demonstrate that AVIC
greater cell-surface expression of TLR2 and TLR4 on AVICs than PVICs. p  0.05
hemokine Release After Stimulation With TLR Agonists
Table 2 Chemokine Release After Stimulation With TLR Agonis
Chemokines
AVICs
Ctrl PGN LPS
IL-8 40 9 11,039 655* 8,736 3
MCP-1 1,666 165 5,540 301* 6,425 1
MIP-1 3.4 0.7 18.5 1.6* 49.8 1
MIP-1 Undetectable 52 6 218 3
IP-10 86 31 75,318 5,647* 331,605 1
RANTES 31 3 6,835 90* 26,226 8
ll values are pg/ml. *p  0.05 versus corresponding control; †p  0.05 versus corresponding tr
Ctrl  control; IL  interleukin; IP  interferon-inducible protein; LPS  lipopolysaccharide; MCP mo
VIC  pulmonary valve interstitial cell; RANTES  regulated upon activation, normal T-cell expressed anhosphate), pH 9.5, for 1 h at 37°C. Color development was
topped with 0.5 N NaOH, and absorbance was measured
t 405 nmol/l. ALP activity was calculated against a
tandard curve and normalized by protein concentration.
esults are expressed in 106 Sigma units/mg protein
U/mg protein). For the stain, cells were fixed and stained
s previously described (12) and photographed with a Nikon
clipse TS100 microscope (Melville, New York).
lizarin red S stain. Cells were fixed and stained with
lizarin red S as previously described (13) and photographed
ith a Nikon Eclipse TS100 microscope. Cryosections
5-m thick) of calcified human aortic valves, stained by the
ame method, served as positive controls.
desitometric data (n  6) show that aortic valves (AVs) express more Toll-like
entative immunoblots of aortic valve interstitial cell (AVIC) and pulmonary valve
ress more TLR2 and TLR4 than PVICs. (C) Flow cytometric data (n  5) show
s corresponding PV/PVICs.
PVICs
Ctrl PGN LPS
59 10 4,913 822*† 3,406 440*†
337 15 3,111 326*† 2,914 275*†
3.0 1.2 13.1 1.5 25.6 4.7*†
Undetectable 37 8 130 24*†
* 496 159 49,470 7,502*† 219,725 11,613*†
81 9 2,587 271*† 8,297 860*†
t in aortic valve interstitial cells (AVICs). n  6.s with
epres
s exp
versuts
62*
79*
0.3*
6*
5,186
93*
eatmen
nocyte chemoattractant protein; MIP macrophage inflammatory protein; PGN  peptidoglycan;
d secreted; TLR  toll-like receptor; Undetectable  below test range.
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Comparison of Aortic and Pulmonary Valves February 10, 2009:491–500tatistical analysis. Data are presented as mean  stan-
ard error of the mean. Analysis of variance with a post-hoc
onferroni/Dunn test was performed to analyze differences
etween experimental groups, and differences were con-
rmed with Kruskal-Wallis and Mann-Whitney U tests.
tatistical significance was accepted within a 95% confi-
ence limit.
esults
xpression of TLR2 and TLR4 is greater in aortic valves
han in pulmonary valves. We compared TLR2 and
LR4 protein levels in aortic and pulmonary valves from
he same human heart. TLR2 and TLR4 levels in aortic
alve tissue homogenate were 1.7 and 2.4 (both p 0.05),
espectively, those in pulmonary valve tissue homogenate
Fig. 1A). TLR2 and TLR4 expression in AVIC lysates
ere 1.9 and 2.6 (both p  0.05), respectively, those in
VIC lysates (Fig. 1B). Cell-surface levels of TLR2 and
LR4 in AVICs were 2.0 and 1.8 (both p  0.05),
espectively, those in PVICs (Fig. 1C).
VICs exhibit a stronger pro-inflammatory response to
LR2 and TLR4 stimulation than PVICs. We then
ssessed whether greater TLR2 and TLR4 expression in
VICs results in a more robust inflammatory response.
fter stimulating AVICs and PVICs for 24 h with the
LR2 and TLR4 agonists peptidoglycan and lipopoly-
accharide, respectively, chemokine release from AVICs
as greater than from PVICs (Table 2). Release of
nterleukin-8, monocyte chemoattractant protein-1,
nterferon-inducible protein-10, and RANTES (regu-
ated upon activation, normal T-cell expressed and se-
reted) was significantly higher from AVICs than PVICs
Figure 2 AVICs Exhibit a Stronger Pro-Osteogenic Response to
Stimulation Than PVICs, and Their BMP-2 Response I
(A) Representative immunoblots of AVIC and PVIC lysates with desitometric data (
induces expression of bone morphogenetic protein (BMP)-2 and runt-related transc
change BMP-4 expression in AVICs or PVICs. p  0.05 versus corresponding controls; †fter stimulation with either peptidoglycan or lipopoly-
accharide, whereas release of macrophage inflammatory
rotein-1 and MIP-1 was significantly greater after
ipopolysaccharide but not peptidoglycan stimulation.
herefore, AVICs have a stronger pro-inflammatory
esponse to TLR2 and TLR4 activation than PVICs.
timulating TLR2 and TLR4 induces BMP-2 and
unx2 in AVICs, but not in PVICs. Next we assessed
hether greater TLR2 and TLR4 expression in AVICs
esults in greater expression of the pro-osteogenic factors
MP-2, BMP-4, and Runx2. Stimulating AVICs with
eptidoglycan and lipopolysaccharide for 24 h up-regulated
MP-2 expression to 4.7 and 4.1 control, and Runx2
xpression to 5.3 and 4.7 control, respectively (Fig. 2A).
timulation with peptidoglycan and lipopolysaccharide did
ot greatly influence BMP-2 or Runx2 expression in PVICs
Fig. 2A), nor did it influence BMP-4 expression in either
VICs or PVICs (Fig. 2B).
ilencing TLR2 and TLR4 in AVICs attenuates
eptidoglycan- and lipopolysaccharide-induced BMP-2
xpression. Since the higher TLR2 and TLR4 levels in
VICs are associated with greater BMP-2 expression, we
hen examined whether reducing TLR2 and TLR4 levels in
VICs by silencing would reduce the BMP-2 response to
eptidoglycan and lipopolysaccharide stimulation. Treating
VICs with siRNA reduced TLR2 and TLR4 levels by
1% and 57%, respectively (Fig. 2C). Silencing TLR2
educed peptidoglycan-stimulated BMP-2 expression 42%,
nd silencing TLR4 reduced lipopolysaccharide-stimulated
MP-2 expression 62%, compared with controls (Fig. 2D).
herefore, reducing TLR2 and TLR4 levels in AVICs to
and TLR4
uced by Silencing TLR2 and TLR4
) show that 24-h stimulation with peptidoglycan (PGN) or lipopolysaccharide (LPS)
factor 2 (Runx2) in AVICs but not in PVICs. (B) PGN and LPS stimulation do notTLR2
s Red
n  3
riptionp  0.05 versus corresponding PVICs. Continued on next page.
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VIC levels.
timulating TLR2 and TLR4 promotes ALP activity in
VICs. Because peptidoglycan and lipopolysaccharide
p-regulated BMP-2 and Runx2 in AVICs, we assessed
hether they up-regulate ALP activity, a biomarker of
arly osteogenesis (14). After stimulating AVICs and
VICs with peptidoglycan and lipopolysaccharide for 14
ays, ALP activity did not increase (Fig. 3A).
Others have reported that culturing AVICs in condition-
ng medium can induce ALP activity (9,10). Indeed, cul-
uring our AVICs and PVICs in conditioning medium
ncreased ALP activity, and stimulation with peptidoglycan
Figure 2 Continued
(C) Treatment with TLR2 small interfering ribonucleic acid (siRNA) (siT2, 60 nmol/
p  0.05 versus controls or scrambled siRNA controls (Scram). n  3. (D) Silen
p  0.05 versus corresponding untreated group; †p  0.05 versus PGN/LPS-treand lipopolysaccharide increased ALP activity further (Fig. 1B). ALP activity in AVICs cultured in conditioning
edium was significantly greater than in AVICs cultured in
rowth medium (1.10  0.07 U/mg vs. 0.47  0.03
U/mg protein, p  0.05) and further increased by stimu-
ation with peptidoglycan and lipopolysaccharide (2.07 
.17 U/mg and 2.11  0.15 U/mg protein, respectively,
oth p  0.01 vs. AVICs cultured in conditioning medium
lone) (Fig. 3B). Stimulation with peptidoglycan and lipo-
olysaccharide also enhanced ALP activity in PVICs grown
n conditioning medium but not significantly (p  0.05).
ore importantly, ALP activity in peptidoglycan- and
ipopolysaccharide-stimulated AVICs was significantly
reater (p  0.01) than in PVICs (1.06  0.19 U/mg and
TLR4 siRNA (siT4, 60 nmol/l) reduced TLR2 and TLR4 expression in AVICs.
R2 and TLR4 attenuated PGN- and LPS-stimulated BMP-2 expression in AVICs.
ntrols or scrambled siRNA controls. n  3. Abbreviations as in Figure 1.l) and
cing TL
ted co.06  0.18 U/mg protein, respectively) (Fig. 3B).
496 Yang et al. JACC Vol. 53, No. 6, 2009
Comparison of Aortic and Pulmonary Valves February 10, 2009:491–500Figure 3 PGN and LPS Up-Regulate ALP Activity in VICs Cultured in CM in a TLR2- and TLR4-Dependent Manner
(A) Alkaline phosphatase (ALP) activity stain and assay show that ALP activity in AVICs and PVICs cultured in growth medium is unchanged despite stimulation with PGN
or LPS for 14 days. n  6. (B) AVICs and PVICs cultured in growth or conditioning medium (CM) were stimulated with PGN or LPS for 14 days. ALP activity stains (repre-
sentative of 6 experiments) show that AVICs exhibit greater PGN/LPS-stimulated ALP activity than PVICs. ALP activity assay shows that AVICs grown in CM have greater
ALP activity than control AVICs grown in growth medium (p  0.05), which is further enhanced after stimulation with PGN or LPS (†p  0.01 vs. AVICs in CM). Neither
PGN nor LPS significantly increases ALP activity of PVICs grown in CM. ALP activity of PGN- or LPS-stimulated AVICs is significantly greater than that of PVICs (‡p  0.01
vs. corresponding PVICs). n  6. (C) ALP activity assay and stain show that treatment with TLR2 siRNA (siTLR2) and TLR4 siRNA (siTLR4) reduces PGN- and LPS-induced
ALP activity in AVICs cultured in CM. p  0.05 versus corresponding control or scrambled siRNA-treated control (scrambled); †p  0.05 versus PGN/LPS-treated control
or scrambled siRNA-treated control. n  3. VIC  valve interstitial cell; other abbreviations as in Figures 1 and 2.
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February 10, 2009:491–500 Comparison of Aortic and Pulmonary Valvesilencing TLR2 and TLR4 attenuates peptidoglycan-
nd lipopolysaccharide-induced ALP activity. Our ear-
ier results and our previous report (5) demonstrate that
timulating AVICs with TLR2 and TLR4 agonists is associ-
ted with expression of pro-osteogenic mediators. There-
ore, we reduced TLR2 and TLR4 levels via silencing to
etermine whether TLR2 and TLR4 are linked to ALP
xpression and whether the ALP response correlates to
LR2 or TLR4 levels in AVICs. Peptidoglycan and lipo-
olysaccharide stimulation increased ALP activity to twice
hat of cells grown in conditioning medium alone (Fig.
B), but silenced TLR2 and TLR4 reduced ALP activity
y one-half, to the level of cells grown in conditioning
edium alone (Fig. 3C).
timulating TLR2 and TLR4 in AVICs promotes calci-
ed nodule formation. To determine whether TLR stim-
lation increases cellular calcification, we stimulated cells
rown in conditioning medium with peptidoglycan or
ipopolysaccharide for 28 days. Peptidoglycan and lipopoly-
accharide promoted calcified nodule formation in AVICs
nd PVICs cultured in conditioning medium, but more and
arger nodules were formed in AVICs than in PVICs (Fig. 4).
either peptidoglycan nor lipopolysaccharide induced calcifi-
ation in cells cultured in growth medium (not shown).
MP-2 is involved in the enhancement of ALP activity
y TLR stimulation in AVICs. Because peptidoglycan-
nd lipopolysaccharide-stimulated AVICs up-regulate
oth BMP-2 protein expression and ALP activity, we
ssessed whether BMP-2 is involved in up-regulating
eptidoglycan- and lipopolysaccharide-induced ALP activ-
ty in AVICs. When AVICs stimulated with peptidoglycan
Figure 4 Stimulation With PGN and LPS Induces Calcified Nodu
AVICs and PVICs were cultured in conditioning medium (CM) and incubated with PG
more and bigger calcified clusters in AVICs than PVICs. The upper right inset show
calcium deposits. Abbreviations as in Figures 1 and 2.nd lipopolysaccharide were treated with the BMP antag- (nist Noggin, ALP activity decreased to 1.13  0.03
U/mg and 0.96 0.03 U/mg protein, respectively, (both
 0.05 vs. stimulated AVICs without Noggin treatment),
hich is similar to the level detected in unstimulated AVICs
1.10  0.07 U/mg protein in AVICs cultured in condi-
ioning medium alone) (Fig. 5A).
Then we examined whether BMP-2 is sufficient to
p-regulate ALP activity in AVICs. Treatment with re-
ombinant BMP-2 did not increase ALP activity in AVICs
ultured in growth medium, but significantly increased ALP
ctivity in cells grown in conditioning medium (1.98 0.19
U/mg vs. 1.10  0.07 U/mg protein, p  0.01) (Fig.
B), to a level comparable to that induced by peptidoglycan
r lipopolysaccharide stimulation (2.07  0.17 U/mg and
.11  0.15 U/mg protein, respectively) (Fig. 3B).
VICs isolated from stenotic valves exhibit greater
LR2, TLR4, and BMP-2 expression. Because our ear-
ier results suggest that differences in TLR2 and TLR4
xpression play a critical role in aortic valve calcification,
e assessed TLR2 and TLR4 expression in AVICs
solated from calcified stenotic valves. TLR2 and TLR4
evels in AVICs from stenotic valves are 2.8 and 2.0,
espectively, those in normal AVICs (Fig. 6A). Basal
MP-2 expression is greater in AVICs from stenotic
alves than in AVICs from normal valves. In addition,
fter 24-h stimulation with peptidoglycan or lipopolysac-
haride, BMP-2 expression is 2.6 and 4.1 greater, respec-
ively, in AVICs from stenotic valves than those from
ormal valves (Fig. 6B). AVICs from stenotic valves tend to
pontaneously cluster and form nodules in long-term culture
rmation in AVICs
LPS for 28 days. Alizarin red S stains (representative of 3 experiments) show
lizarin red S-stained stenotic aortic valve as a positive control. Arrows indicatele Fo
N or
s an Adata not shown).
DI
a
m
v
g
h
d
498 Yang et al. JACC Vol. 53, No. 6, 2009
Comparison of Aortic and Pulmonary Valves February 10, 2009:491–500iscussion
t is well known that calcification occurs more frequently in
ortic valves than in pulmonary valves, but the underlying
echanisms are unclear. It has been proposed that aortic
alve calcification is related to the higher oxygen tension and
Figure 5
ALP Activity in AVICs Induced by PGN and LPS
Is Abolished by BMP Antagonism With Noggin and
Mimicked by Stimulation With Recombinant BMP-2
(A) Aortic valve interstitial cells (AVICs) grown in CM were stimulated with PGN
or LPS and treated with (Nog) or without Noggin (Nog) for 14 days. ALP
activity stain and assay demonstrate that treatment with Noggin attenuates
ALP activity in AVICs. p  0.05 versus Nog. n  3. (ALP activity is
expressed as a percentage of ALP activity in AVICs cultured in CM.) (B) AVICs
were grown in growth or CM with or without bone morphogenetic protein
(BMP)-2 for 14 days. ALP activity stain and assay show that although BMP-2
does not induce ALP activity in AVICs grown in growth medium, it does
increase ALP activity in AVICs grown in CM. p  0.01 versus CM. n  5.
Abbreviations as in Figure 3.reater transvalvular pressure present on the left side of the (eart. A few studies have found differences in vimentin
istribution (15) and smooth muscle alpha-actin expression
Figure 6 AVICs From Stenotic Valves
Express More TLR2, TLR4, and BMP-2
(A) Representative immunoblots with desitometric data (n  3) demonstrate
that aortic valve interstitial cells (AVICs) from stenotic valves express more
Toll-like receptor (TLR)2 and TLR4 than AVICs from normal valves. p  0.01
versus corresponding normal AVICs. (B) AVICs from stenotic valves express
more BMP-2 under basal conditions and after 24-h stimulation with PGN (10
g/ml) and LPS (200 ng/ml) than normal AVICs. p  0.05 versus normal con-
trol (Ctrl); †p  0.01 versus normal LPS treated; ‡p  0.05 versus normal
PGN treated. n  3. VIC  valve interstitial cell; other abbreviations as in
Figure 2.16) in aortic and pulmonary valves. In this study, using
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February 10, 2009:491–500 Comparison of Aortic and Pulmonary Valvesortic and pulmonary valves from the same heart, we
dentified a novel difference between the valves: greater
xpression of TLR2 and TLR4 in aortic valves than
ulmonary valves, whether in valve tissue, in isolated inter-
titial cells, or on cell surfaces. There were variations in
LR2 and TLR4 levels in different hearts, but in each
eart, TLR2 and TLR4 levels were consistently greater in
ortic valve tissue and cells than in pulmonary valve tissue
nd cells.
Not only do AVICs express more TLR2 and TLR4 than
VICs, but AVICs produce a stronger pro-inflammatory
esponse to TLR2 and TLR4 stimulation than PVICs.
everal studies have suggested that inflammation is involved
n the pathogenesis of aortic valve calcification (17) and that
ICs participate in the inflammatory process (6). Our
esults, which are the first to demonstrate that AVICs have
reater pro-inflammatory potential than PVICs, suggest
hat AVICs play an important role in the inflammatory
esponse in aortic valves and support the importance of
nflammation in the pathogenesis of aortic stenosis.
We previously reported that stimulating human AVICs
ith TLR2 and TLR4 agonists up-regulates BMP-2 and
unx2 (5), which have both been found in calcified aortic
alves (7,8). In this study, we found that stimulation with
LR2 and TLR4 agonists induced BMP-2 and Runx2
xpression in AVICs but not in PVICs. And although
LR2 and TLR4 expression in AVICs is only twice that in
VICs, peptidoglycan- and lipopolysaccharide-induced
MP-2 and Runx2 expression is 4 to 5 greater in AVICs.
ilencing TLR2 and TLR4, which halved receptor levels,
educed peptidoglycan- and lipopolysaccharide-induced
MP-2 and Runx2 expression by a factor of 2 to 3.
herefore, peptidoglycan- and lipopolysaccharide-induced
MP-2 and Runx2 expression is mainly mediated by TLR2
nd TLR4.
In VICs, ALP activity and calcified nodule formation are
arkers of a change to an osteogenic phenotype (10,18).
timulation with TLR2 and TLR4 agonists induced greater
LP activity and calcified nodule formation in AVICs than
VICs cultured in conditioning medium. Therefore,
VICs are more likely to be activated to a pro-osteogenic
henotype than PVICs, and pro-osteogenic phenotypic
hanges in human AVICs are promoted by TLR2 and
LR4 stimulation. In addition, because silencing TLR2
nd TLR4 reduced ALP activity to the level in cells
ultured in conditioning medium, peptidoglycan- and
ipopolysaccharide-induced ALP activity is mainly mediated
y TLR2 and TLR4. It should be noted that neither
eptidoglycan nor lipopolysaccharide could increase ALP
ctivity or calcified nodule formation in VICs cultured in
rowth medium, which does not have the additional osteo-
enic factors present in conditioning medium. This indi-
ates that pro-osteogenic changes in VICs are complex and
ultifactorial.
AVICs stimulated with TLR2 and TLR4 agonists up-egulate both BMP-2 expression and ALP activity. When pVICs were stimulated with recombinant BMP-2, ALP
ctivity in AVICs cultured in conditioning medium in-
reased to a level similar to that induced by peptidoglycan or
ipopolysaccharide. This confirmed the results of Osman
t al. (9) under our experimental conditions. In addition, the
MP antagonist Noggin attenuated the lipopolysaccharide-
nd peptidoglycan-induced augmentation of ALP activity.
ogether, these results indicate that BMP-2 is involved in
he peptidoglycan- or lipopolysaccharide-stimulated aug-
entation of ALP activity in AVICs. We should note that
oggin antagonizes other BMPs also, including BMP-4
19). It is unlikely that Noggin’s effects on ALP activity
ere mediated through BMP-4 because neither peptidogly-
an nor lipopolysaccharide stimulation up-regulated
MP-4. But it is possible that other BMPs contribute to
he effects of these TLR agonists on ALP activity, and that
ttenuation of these effects by Noggin is not only due to
ntagonism of BMP-2.
A comparison of AVICs from normal and stenotic valves
eveals that AVICs from stenotic valves express even more
LR2 and TLR4 than normal AVICs. In addition, basal
MP-2 expression is greater in AVICs from stenotic valves
han those from normal valves, and is further increased by
timulation with TLR agonists. This is consistent with
tudies that found greater expression of BMP-2 in calcified
tenotic heart valves (7). It also demonstrates that AVICs
rom stenotic valves are phenotypically altered. Indeed,
hose AVICs tend to spontaneously form nodules in culture.
herefore, parallel experiments to examine ALP expression
n response to long-term TLR stimulation are not feasible
nder our experimental conditions.
tudy limitations. Among the limitations of this study
re its relatively small sample size (6 normal aortic and
ulmonary valves, 3 stenotic aortic valves). In addition,
e examined only VICs. Although their role in valve
alcification and stenosis continues to emerge, some
tudies suggest that endothelial damage or dysfunction
nitiates the process of valve calcification in vivo (20).
ur study did not address the possible role of endothelial
ells or other cell types in valve calcification. In addition,
e used cultured VICs, which, like all cultured cells,
ight have changed some of the characteristics they had
n vivo. We should note, however, that in our earlier
tudy we found that levels of TLR2 and TLR4 in human
VICs were similar in newly isolated and repeatedly
assaged cells (5).
Further, stimulating these cells with peptidoglycan and
ipopolysaccharide is in itself an artificial experimental
onstruct, since it is unknown whether VICs are exposed to
athogenic components in vivo. And although we used low
oncentrations of peptidoglycan and lipopolysaccharide, we
annot rule out TLR-independent effects of these agonists
n the expression of pro-inflammatory and pro-osteogenic
actors. In addition, recent studies have suggested that
ontaminants in a commercially prepared S. aureus-derived
eptidoglycan preparation may contribute to TLR2 activa-
t
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Comparison of Aortic and Pulmonary Valves February 10, 2009:491–500ion (21); however, it is agreed that this preparation indeed
ctivates TLR2.
onclusions
n this study, we demonstrated that TLR2 and TLR4
xpression are greater in human aortic valves than in
ulmonary valves, and that after stimulation with TLR2 and
LR4 agonists, AVICs demonstrate greater expression of
ro-inflammatory and pro-osteogenic mediators and greater
steogenic phenotypic changes than PVICs. Although
LR2 and TLR4 levels in AVICs are only twice those in
VICs, stimulation with TLR agonists induces changes in
ro-osteogenic mediator expression and osteogenic pheno-
ype that are many times greater in AVICs than PVICs.
ecause these changes are attenuated by reducing TLR2
nd TLR4 levels in AVICs to their levels in PVICs, and
ecause TLR2 and TLR4 expression in AVICs from
tenotic valves is even greater than their expression in
ormal AVICs, this study demonstrates that TLR2 and
LR4 play a critical role in mediating the pro-inflammatory
nd pro-osteogenic responses and osteogenic phenotypic
hanges in AVICs in vitro. Many other factors likely
ontribute to aortic valve calcification in vivo, including lipid
nfiltration, matrix protein remodeling, aging, and shear
tress. But this study suggests that the TLR2- and TLR4-
ediated inflammatory and osteogenic responses play an
mportant role in the pathogenesis of aortic valve calcifica-
ion and stenosis.
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